Combination Therapy with LAK and Dendritic Cells for Cancer Treatment
Author Information
Author(s): West E J, Scott K J, Jennings V A, Melcher A A
Primary Institution: Cancer Research UK Clinical Centre, St James's University Hospital
Hypothesis
Can combination therapy using lymphokine-activated killer cells (LAKs) and dendritic cells (DCs) enhance anti-tumor immunity?
Conclusion
The combination of clinical-grade LAKs and DCs is an effective immunotherapy for stimulating both innate and adaptive anti-tumor immunity in cancer patients.
Supporting Evidence
- LAKs can enhance the maturation of DCs, leading to improved immune responses.
- Co-culture of LAKs and DCs resulted in increased production of inflammatory cytokines.
- LAKs showed enhanced cytotoxicity against tumor cells when activated by DCs.
- Combination therapy improved the priming of specific anti-tumor CTLs.
Takeaway
This study shows that using two types of immune cells together can help the body fight cancer better than using just one type.
Methodology
The study involved co-culturing LAKs and DCs to monitor their activation and immune responses against melanoma targets.
Participant Demographics
Healthy donors and melanoma patients were used to isolate PBMCs for the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website